Long-Term Follow-Up Data from the Shunt Design TrialKestle J.a · Drake J.b · Milner R.h · Sainte-Rose C.c · Cinalli G.c · Boop F.d · Piatt J.e · Haines S.f · Schiff S.g · Cochrane D.h · Steinbok P.h · MacNeil N.h
aDivision of Pediatric Neurosurgery, Primary Children’s Medical Center, University of Utah, Salt Lake City, Utah, USA; bDivision of Neurosurgery, Hospital for Sick Children, Toronto, Canada; cService de Neurochirurgie, Hôpital Necker Enfants Malades, Paris, France; dDivision of Neurosurgery, Arkansas Children’s Hospital, Little Rock, Ark.; eDivision of Neurosurgery, Oregon Health Sciences University, Portland, Oreg.; fDivision of Neurosurgery, University of Minnesota, Minneapolis, Minn.; gDivision of Neurosurgery, Children’s National Medical Center, Washington, D.C., USA; hDivision of Neurosurgery, B.C.’s Children’s Hospital, Vancouver, Canada
Background: A previously reported multicenter randomized trial assessed whether 2 new shunt valve designs would reduce shunt failure rates compared to differential pressure valves. The study did not show a significant difference in the time to first shunt failure. Patients entered the trial between October 1, 1993, and October 31, 1995. The primary results were based on the patients’ status as of October 31, 1996 (a minimum follow-up of 1 year). This report describes the late complications based on the patients’ most recent follow-up. Methods: Three hundred and forty-four hydrocephalic children at 12 North American and European centers were randomized to 1 of 3 valves: a standard differential pressure valve; a Delta valve (PS Medical-Medtronic) or a Sigma valve (NMT Cordis). Patients were followed until their first shunt failure. Shunt failure was defined as shunt surgery for obstruction, overdrainage, loculation or infection. If the shunt did not fail, follow-up was continued until August 31, 1999. Results: One hundred and seventy-seven patients had shunt failure. Shunt obstruction occurred in 131, overdrainage in 13, loculated ventricles in 2 and infection in 29. The overall shunt survival was 62% at 1 year, 52% at 2 years, 46% at 3 years, 41% at 4 years. The survival curves for the 3 valves were similar to those from the original trial and did not show a survival advantage for any particular valve. Conclusions: Prolonged follow-up to date does not alter the primary conclusions of the trial: there does not appear to be one valve that is clearly the best for the initial treatment of pediatric hydrocephalus.
© 2001 S. Karger AG, Basel
John Kestle, MD
Division of Pediatric Neurosurgery, Primary Children’s Medical Center
100 North Medical Drive
Salt Lake City, UT 84113 (USA)
Tel. +1 801 588 3400, Fax +1 801 588 3409, E-Mail firstname.lastname@example.org
The collaborators are listed in the appendix.
Received: Received: July 31, 2000
Accepted: September 13, 2000
Number of Print Pages : 7
Number of Figures : 6, Number of Tables : 3, Number of References : 5
Founded 1985 by E.B. Hendrick and D.H. Reigel; Editor-in-Chief 1992–1996: F.J. Epstein
Official Journal of the American Society of Pediatric Neurosurgeons (ASPN)
Vol. 33, No. 5, Year 2000 (Cover Date: November 2000)
Journal Editor: D.G. McLone, Chicago, Ill.
ISSN: 1016–2291 (print), 1423–0305 (Online)
For additional information: http://www.karger.com/journals/pne